Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
Drugs Made In America Acquisition Corp. Rights (DMAAR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: DMAAR (1-star) is a SELL. SELL since 1 days. Simulated Profits (11.11%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 0% | Avg. Invested days 21 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 0.09 - 0.17 | Updated Date 05/1/2025 |
52 Weeks Range 0.09 - 0.17 | Updated Date 05/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Drugs Made In America Acquisition Corp. Rights
Company Overview
History and Background
Drugs Made In America Acquisition Corp. is a blank check company incorporated for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.
Core Business Areas
- Special Purpose Acquisition Company (SPAC): Drugs Made In America Acquisition Corp. focuses on identifying and acquiring a target company in the pharmaceutical and healthcare sector.
Leadership and Structure
The company is led by its board of directors and management team. Specific details on individuals would require researching current filings as of the current date.
Top Products and Market Share
Key Offerings
- Acquisition Rights: The 'rights' represent the opportunity to purchase shares in the acquired company post-merger. Their value depends entirely on the success and valuation of the target acquisition. No market share data or direct competitors exist as these rights pertain to a specific, future acquisition.
Market Dynamics
Industry Overview
The SPAC market involves raising capital to acquire existing companies. Success is contingent on identifying attractive target companies and favorable market conditions.
Positioning
Drugs Made In America Acquisition Corp. is positioned as a vehicle for investors to participate in a potential pharmaceutical or healthcare acquisition. Its competitive advantage depends on the attractiveness of its eventual target.
Total Addressable Market (TAM)
TAM is difficult to quantify precisely as it depends on the size and type of company it plans to acquire. The entire healthcare and pharmaceutical market is vast, but Drugs Made In America Acquisition Corp.'s success is tied to the individual target and its market positioning within that sector.
Upturn SWOT Analysis
Strengths
- Experienced management team (potentially, depending on the team)
- Access to capital for acquisition
- Potential for high returns if a successful acquisition is made
Weaknesses
- Reliance on identifying and acquiring a suitable target
- Uncertainty regarding the target's future performance
- Dilution of shareholder value upon acquisition
- SPAC structure inherently carries risks and uncertainty
Opportunities
- Acquisition of a high-growth company
- Consolidation within a fragmented industry
- Leveraging technological advancements in healthcare
Threats
- Inability to find a suitable target
- Unfavorable market conditions for acquisitions
- Regulatory changes impacting the healthcare industry
- Increased competition from other SPACs
Competitors and Market Share
Key Competitors
- Numerous SPACs exist in the market. The exact competitors are those pursuing similar acquisition targets
Competitive Landscape
The competitive landscape depends on the specific acquisition target and the other potential acquirers.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is not applicable at this stage.
Future Projections: Future projections are entirely dependent on the target acquisition. There are no solid analyst estimates until a deal is announced.
Recent Initiatives: Recent initiatives focus on identifying potential target companies.
Summary
Drugs Made In America Acquisition Corp. is a SPAC seeking to acquire a company. Its success hinges on identifying a suitable target within the healthcare or pharmaceutical sector and integrating the company's resources. The rights' value is speculative and heavily dependent on this process. Investors face typical SPAC risks.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC filings
- Financial news sources
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investing in SPACs is highly speculative and carries significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Drugs Made In America Acquisition Corp. Rights
Exchange NASDAQ | Headquaters Fort Lauderdale, FL, United States | ||
IPO Launch date 2025-02-25 | CEO & Executive Chairman Ms. Lynn Stockwell | ||
Sector - | Industry - | Full time employees - | Website https://dmaacorp.com |
Full time employees - | Website https://dmaacorp.com | ||
Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. Drugs Made In America Acquisition Corp. was incorporated in 2024 and is based in Fort Lauderdale, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.